Critical Bleeding in Acquired Hemophilia A: Bypassing Agents or Recombinant Porcine Factor VIII?

Introduction

Patients with acquired hemophilia A (AHA) often present in an emergency setting to physicians not specialized in bleeding disorders.[1] If symptoms and laboratory signs are appropriately recognized, physicians will usually consult with experts, who will guide management of the initial bleed, either remotely or after patient referral. In patients with clearly acquired bleeding, isolated prolongation of the activated partial thromboplastin time, and low factor VIII (FVIII) activity, the suspicion of AHA is likely enough to warrant hemostatic treatment in the case of significant bleeding. If time permits, the FVIII inhibitor titer will be quantified by the Bethesda assay (in Bethesda units [BU]/mL), and differential diagnoses (like the acquired von Willebrand syndrome[2] or lupus anticoagulant) will be excluded by appropriate testing, before treatment is commenced.[3] [4]

Although the diagnosis of AHA is usually clear-cut,[5] significant delays occur because of lack of awareness by nonexpert physicians. The European Acquired Hemophilia Registry (EACH2) documented a diagnostic delay of more than a week in 35% of patients, and the median time to start of hemostatic treatment was 20 days in these patients.[6] Delayed diagnosis and treatment may result in the accumulation of more severe tissue damage, in particular of large muscle hematomas, making hemostatic treatment more difficult and failure more likely. In EACH2, the only parameter that differed significantly between patients who responded to treatment and those who did not was a delay in time to treatment (median: 1 vs. 4 days).[7]

This narrative review article discusses the optimal use of existing hemostatic treatment options for patients with AHA, with emphasis on advantages and potential risks of particular agents in certain clinical situations.

The drugs discussed herein are summarized in [Table 1]. The inclusion of the bypassing agents (recombinant factor VIIa [rFVIIa] and activated prothrombin complex concentrate [APCC]) as well as recombinant porcine FVIII (rpFVIII) is based on their European Union (EU) licensing status for AHA and international treatment recommendations.[1] Plasma-derived and recombinant human FVIII concentrates are used only if other treatment options are not available and are therefore not discussed here.

Table 1 Hemostatic agents to treat acute bleeds in AHA

Agent	Recommended starting dose and interval	Laboratory monitoring	Hemostatic effectiveness	Thromboembolic risk
Bypassing agents
Recombinant factor VIIa (eptacog alfa activated, NovoSeven)	90 µg/kg q 2–3 h	None	Systematic review: 84–96%[12] Registries: EACH2 91%[7]	Systematic review: 0–5%[12] Registries: EACH2 2.9%[7]
Activated prothrombin complex concentrate (FEIBA)	50–100 U/kg q 8–12 h[a]	None	Systematic review: not available Registries: EACH2 93%,[7] US 76–100%[30]	Systematic review: not available Registries: EACH2 4.8%[7]
Recombinant porcine FVIII
Susoctocog alfa (Obizur)	200 U/kg q 4–12 h	FVIII one-stage clot assay • 30 min and 3 h after first dose • Before and 30 min after subsequent doses	Systematic review: not available Clinical trial: 100% effective or partially effective at 24 h; 86% control of qualifying bleed[14]	Systematic review: not available Clinical trial: 0%[14]

Abbreviations: AHA, acquired hemophilia A; EACH2, The European Acquired Hemophilia Registry.

^a Maximum daily dose of 200 U/kg body weight must not be exceeded.

Publikationsverlauf

Eingereicht: 18. März 2020

Angenommen: 05. Mai 2020

Artikel online veröffentlicht:
11. September 2020

• References

• 1 Kruse-Jarres R, Kempton CL, Baudo F. et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 2017; 92 (07) 695-705
• 2 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
• 3 Tiede A, Scharf RE, Dobbelstein C, Werwitzke S. Management of acquired haemophilia A. Hamostaseologie 2015; 35 (04) 311-318
• 4 Werwitzke S, Geisen U, Nowak-Göttl U. et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost 2016; 14 (05) 940-947
• 5 Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 2014; 40 (07) 803-811
• 6 Knoebl P, Marco P, Baudo F. et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10 (04) 622-631
• 7 Baudo F, Collins P, Huth-Kühne A. et al; EACH2 Registry Contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120 (01) 39-46
• 8 Lisman T, de Groot PG. The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. Blood Rev 2015; 29 (04) 223-229
• 9 Varadi K, Tangada S, Loeschberger M. et al. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. Haemophilia 2016; 22 (04) 615-624
• 10 Lillicrap D, Schiviz A, Apostol C. et al. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia 2016; 22 (02) 308-317
• 11 Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012; 157 (06) 653-663
• 12 Tiede A, Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol 2018; 97 (10) 1889-1901
• 13 Tiede A, Amano K, Ma A. et al. The use of recombinant activated factor VII in patients with acquired haemophilia. Blood Rev 2015; 29 (Suppl. 01) S19-S25
• 14 Kruse-Jarres R, St-Louis J, Greist A. et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21 (02) 162-170
• 15 Stemberger M, Möhnle P, Tschöp J, Ney L, Spannagl M, Reincke M. Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy. Haemophilia 2016; 22 (05) e472-e474
• 16 Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia 2017; 23 (01) 25-32
• 17 Nguyen S, Teh P, Zhou J, Chang EY, von Drygalski A. Acquired hemophilia A (FVIII deficiency) associated with papillary thyroid cancer: treatment with recombinant porcine FVIII. Case Rep Hematol 2019; 2019: 9026121
• 18 Sally C, Jane M, Ritam P, Harriet A, Stewart H, Huyen T. Acquired haemophilia and haemostatic control with recombinant porcine FVIII: case series. Intern Med J 2020; (e-pub ahead of print)
• 19 Neufeld EJ, Négrier C, Arkhammar P. et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev 2015; 29 (Suppl. 01) S34-S41
• 20 Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14 (01) 39-43
• 21 Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 2013; 39 (02) 191-201
• 22 Türkantoz H, Königs C, Knöbl P. et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01/2010 Study. J Thromb Haemost 2020; 18 (01) 36-43
• 23 Fosbury E, Drebes A, Riddell A, Chowdary P. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A. Ther Adv Hematol 2017; 8 (09) 263-272
• 24 Collins PW, Hirsch S, Baglin TP. et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109 (05) 1870-1877
• 25 Tiede A, Klamroth R, Scharf RE. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125 (07) 1091-1097
• 26 Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia 2008; 14 (04) 736-742
• 27 Tiede A, Huth-Kühne A, Oldenburg J. et al. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol 2009; 88 (04) 365-370
• 28 Tiede A, Giangrande P, Teitel J. et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement. Haemophilia 2019; 25 (06) 969-978
• 29 Möhnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46 (02) 121-123
• 30 Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10 (02) 169-173